ABIVAX Appoints Didier Blondel as Chief Financial Officer

Regulatory News:

ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral diseases, today announced the appointment of Didier Blondel as Chief Financial Officer, effective January 2^nd, 2017.

Mr. Blondel was Chief Financial Officer at Sanofi Pasteur MSD, a Lyon-based joint-venture between Sanofi and Merck, and European leader in human vaccines, since 2012. During the previous 20 year period, Mr. Blondel held a wide scope of senior finance positions at Sanofi, in Commercial Operations and then R&D, where he became Global R&D CFO. Didier Blondel started his career as an auditor at Price Waterhouse Coopers, after graduating from the Commercial Institute of Nancy (ICN), a leading French Business School. He also holds a Master in Finance and Accounting degree from University of Nancy, as well as a Professional Certificate in Finance and Accounting (DESCF).

Alain Chevallier, currently CFO of ABIVAX, will transition to new professional opportunities at Truffle Capital, the majority shareholder of ABIVAX. Mr. Chevallier will continue as a Senior Advisor at ABIVAX.

"I am enthusiastic to welcome Didier as Chief Financial Officer of ABIVAX. His extensive experience in Finance will be a significant addition to the ABIVAX team,” said Prof. Hartmut Ehrlich, M.D., Chief Executive Officer of ABIVAX. "And I warmly thank Alain Chevallier for bringing his unique expertise and tremendous experience to the company and his outstanding contributions in successfully enabling ABIVAX to meet critical milestones, including the company creation in 2013 and our IPO in 2015. We look forward to receiving his continuous support as Senior Advisor.”

"I am thrilled to join ABIVAX with its compelling mission, exciting development portfolio, and dynamic, exceptional team,” said Didier Blondel. "I am very much looking forward to contributing to the success of the company,” he added.

About ABIVAX (www.abivax.com)

ABIVAX is an innovative biotechnology company focused on targeting the immune system to eliminate viral disease. ABIVAX leverages three technology platforms for drug discovery: an anti-viral, an immune enhancement, and a polyclonal antibody platform. ABX464, its most advanced compound, is currently in Phase II clinical trials for providing a functional cure for patients with HIV/AIDS. It is a first-in-class oral small anti-viral molecule which blocks HIV replication through a unique mechanism of action and also has a strong anti-inflammatory effect. In addition, ABIVAX is advancing a clinical stage immune enhancer as well as multiple preclinical candidates against additional viral targets (i.e. Chikungunya, Ebola, Dengue), and several of these compounds are planned to enter clinical development within the next 18 months. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX).

More information on the company is available at www.abivax.com.

Follow us on Twitter @ABIVAX_

View source version on businesswire.com: http://www.businesswire.com/news/home/20161215005739/en/